Other studies identified Fli-1 overexpression as a biomarker of certain cancers including melanoma [21], ovarian cancer [22], endometrial cancer [23], breast cancer [24], and nasopharyngeal carcinoma (NPC) [25]. This evidence concerns the gene FLI1 and nasopharyngeal carcinoma.